Alfred Sandrock Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Alfred Sandrock.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Alfred Sandrock. Alfred Sandrock is EVP CMO Neuro & Neurodegenerat in BIOGEN INC. ($IDPH) and EVP, Chief Medical Officer in BIOGEN INC. ($IDPH) and EVP, Research & Development in BIOGEN INC. ($IDPH) and Grp SVP, Chief Medical Officer in BIOGEN INC. ($IDPH) and Head of Research & Development in BIOGEN INC. ($IDPH) and Director in NEUROCRINE BIOSCIENCES INC ($NBIX).
Latest Insider Trading Transactions of Alfred Sandrock
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 09 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | Head of Research & ... | Sell | S | 440.00 | 7,672 | 3,375,680 | 10,169 | 17.8 K to 10.2 K (-43.00 %) |
Jun 09 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | Head of Research & ... | Sell | S | 440.00 | 7,672 | 3,375,680 | 10,169 | 17.8 K to 10.2 K (-43.00 %) |
Feb 22 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | A | 0.00 | 14,500 | 0 | 14,500 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | J | 0.00 | 2,310 | 0 | 8,042 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 1,708 | 0 | 10,352 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | J | 0.00 | 1,996 | 0 | 3,446 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 1,446 | 0 | 5,442 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | J | 0.00 | 1,466 | 0 | 0 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 1,300 | 0 | 1,466 | |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 278.03 | 758 | 210,747 | 17,738 | 18.5 K to 17.7 K (-4.10 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 278.03 | 642 | 178,495 | 18,496 | 19.1 K to 18.5 K (-3.35 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 278.03 | 577 | 160,423 | 19,138 | 19.7 K to 19.1 K (-2.93 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 1,708 | 0 | 19,715 | 18 K to 19.7 K (+9.49 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 1,446 | 0 | 18,007 | 16.6 K to 18 K (+8.73 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 1,300 | 0 | 16,561 | 15.3 K to 16.6 K (+8.52 %) |
Feb 17 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 278.03 | 1,533 | 426,220 | 15,261 | 16.8 K to 15.3 K (-9.13 %) |
Jan 29 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Grant | A | 0.00 | 3,728 | 0 | 16,794 | 13.1 K to 16.8 K (+28.53 %) |
Jan 29 2021 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Grant | A | 0.00 | 3,728 | 0 | 16,794 | 13.1 K to 16.8 K (+28.53 %) |
Nov 06 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Sell | S | 350.00 | 1,500 | 525,000 | 13,066 | 14.6 K to 13.1 K (-10.30 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | A | 0.00 | 12,060 | 0 | 12,060 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | J | 0.00 | 1,859 | 0 | 6,888 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 1,583 | 0 | 8,747 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | J | 0.00 | 1,340 | 0 | 2,766 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 1,422 | 0 | 4,106 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Option Exercise | M | 0.00 | 2,211 | 0 | 0 | |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 331.76 | 703 | 233,227 | 13,806 | 14.5 K to 13.8 K (-4.85 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 1,583 | 0 | 14,509 | 12.9 K to 14.5 K (+12.25 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 331.76 | 538 | 178,487 | 12,926 | 13.5 K to 12.9 K (-4.00 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 1,422 | 0 | 13,464 | 12 K to 13.5 K (+11.81 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Payment of Exercise | F | 331.76 | 660 | 218,962 | 12,042 | 12.7 K to 12 K (-5.20 %) |
Feb 14 2020 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Research & Dev ... | Buy | M | 0.00 | 2,211 | 0 | 12,702 | 10.5 K to 12.7 K (+21.08 %) |
May 23 2019 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 79.79 | 10,000 | 797,900 | 10,000 | |
Feb 26 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 819 | 0 | 0 | |
Feb 26 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,663 | 0 | 819 | |
Feb 26 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 325.33 | 739 | 240,419 | 10,409 | 11.1 K to 10.4 K (-6.63 %) |
Feb 26 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,663 | 0 | 11,148 | 9.5 K to 11.1 K (+17.53 %) |
Feb 20 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 808 | 0 | 2,128 | |
Feb 20 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,318 | 0 | 2,936 | |
Feb 20 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 332.87 | 586 | 195,062 | 9,485 | 10.1 K to 9.5 K (-5.82 %) |
Feb 20 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,318 | 0 | 10,071 | 8.8 K to 10.1 K (+15.06 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 1,188 | 0 | 5,528 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,574 | 0 | 6,716 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 1,453 | 0 | 0 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,965 | 0 | 1,453 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,104 | 0 | 2,211 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | A | 0.00 | 10,330 | 0 | 10,330 | |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 319.43 | 699 | 223,282 | 8,753 | 9.5 K to 8.8 K (-7.40 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,574 | 0 | 9,452 | 7.9 K to 9.5 K (+19.98 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 319.43 | 873 | 278,862 | 7,878 | 8.8 K to 7.9 K (-9.98 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,965 | 0 | 8,751 | 6.8 K to 8.8 K (+28.96 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 319.43 | 588 | 187,825 | 6,786 | 7.4 K to 6.8 K (-7.97 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 319.43 | 358 | 114,356 | 7,374 | 7.7 K to 7.4 K (-4.63 %) |
Feb 14 2019 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,104 | 0 | 7,732 | 6.6 K to 7.7 K (+16.66 %) |
May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
Feb 28 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Sell | S | 290.83 | 259 | 75,325 | 6,553 | 6.8 K to 6.6 K (-3.80 %) |
Feb 26 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 843 | 0 | 2,482 | |
Feb 26 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,635 | 0 | 3,325 | |
Feb 26 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 284.81 | 727 | 207,057 | 7,461 | 8.2 K to 7.5 K (-8.88 %) |
Feb 26 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,635 | 0 | 8,188 | 6.6 K to 8.2 K (+24.95 %) |
Feb 21 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Sell | S | 292.00 | 743 | 216,956 | 6,553 | 7.3 K to 6.6 K (-10.18 %) |
Feb 20 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Sell | S | 298.85 | 1,294 | 386,712 | 7,296 | 8.6 K to 7.3 K (-15.06 %) |
Feb 20 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 787 | 0 | 4,254 | |
Feb 20 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 1,339 | 0 | 5,041 | |
Feb 20 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 299.38 | 596 | 178,430 | 8,590 | 9.2 K to 8.6 K (-6.49 %) |
Feb 20 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 1,339 | 0 | 9,186 | 7.8 K to 9.2 K (+17.06 %) |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | J | 0.00 | 1,398 | 0 | 3,418 | |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | M | 0.00 | 2,012 | 0 | 4,816 | |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | A | 0.00 | 8,290 | 0 | 8,290 | |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Option Exercise | A | 0.00 | 3,315 | 0 | 3,315 | |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 316.63 | 718 | 227,340 | 7,847 | 8.6 K to 7.8 K (-8.38 %) |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Buy | M | 0.00 | 2,012 | 0 | 8,565 | 6.6 K to 8.6 K (+30.70 %) |
Feb 14 2018 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP, Chief Medical ... | Payment of Exercise | F | 316.63 | 598 | 189,345 | 6,553 | 7.2 K to 6.6 K (-8.36 %) |
Jun 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 53.64 | 15,000 | 804,600 | 15,000 | |
Apr 04 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Sell | S | 274.08 | 1,981 | 542,952 | 7,060 | 9 K to 7.1 K (-21.91 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 815 | 0 | 0 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 628 | 0 | 0 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 1,569 | 0 | 6,828 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 398 | 0 | 1,062 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 1,375 | 0 | 4,960 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 662 | 0 | 1,460 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 1,103 | 0 | 6,335 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 738 | 0 | 628 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 1,841 | 0 | 8,397 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 274.76 | 384 | 105,508 | 10,014 | 10.4 K to 10 K (-3.69 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 815 | 0 | 10,398 | 9.6 K to 10.4 K (+8.50 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 274.60 | 296 | 81,282 | 9,583 | 9.9 K to 9.6 K (-3.00 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 628 | 0 | 9,879 | 9.3 K to 9.9 K (+6.79 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 274.76 | 739 | 203,048 | 9,251 | 10 K to 9.3 K (-7.40 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 1,569 | 0 | 9,990 | 8.4 K to 10 K (+18.63 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 274.76 | 727 | 199,751 | 8,421 | 9.1 K to 8.4 K (-7.95 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 284.75 | 188 | 53,533 | 9,148 | 9.3 K to 9.1 K (-2.01 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 398 | 0 | 9,336 | 8.9 K to 9.3 K (+4.45 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 287.63 | 647 | 186,097 | 8,938 | 9.6 K to 8.9 K (-6.75 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 1,375 | 0 | 9,585 | 8.2 K to 9.6 K (+16.75 %) |
Feb 17 2017 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | A | 0.00 | 6,380 | 0 | 6,380 | |
May 24 2016 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 47.89 | 15,000 | 718,350 | 15,000 | |
Feb 26 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Sell | S | 261.90 | 183 | 47,928 | 7,990 | 8.2 K to 8 K (-2.24 %) |
Feb 25 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 689 | 0 | 2,074 | |
Feb 25 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 347 | 0 | 2,763 | |
Feb 25 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 258.99 | 164 | 42,474 | 8,173 | 8.3 K to 8.2 K (-1.97 %) |
Feb 25 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 347 | 0 | 8,337 | 8 K to 8.3 K (+4.34 %) |
Feb 24 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | A | 0.00 | 7,270 | 0 | 7,270 | |
Feb 19 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Sell | S | 256.16 | 722 | 184,948 | 7,990 | 8.7 K to 8 K (-8.29 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 1,900 | 0 | 10,006 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | J | 0.00 | 759 | 0 | 1,336 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 792 | 0 | 797 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 573 | 0 | 2,095 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 1,434 | 0 | 11,906 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 247.22 | 373 | 92,213 | 8,712 | 9.1 K to 8.7 K (-4.11 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 792 | 0 | 9,085 | 8.3 K to 9.1 K (+9.55 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 247.22 | 270 | 66,749 | 8,293 | 8.6 K to 8.3 K (-3.15 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 573 | 0 | 8,563 | 8 K to 8.6 K (+7.17 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 247.22 | 556 | 137,454 | 7,990 | 8.5 K to 8 K (-6.51 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 1,434 | 0 | 8,546 | 7.1 K to 8.5 K (+20.16 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 247.22 | 628 | 155,254 | 7,112 | 7.7 K to 7.1 K (-8.11 %) |
Feb 10 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Option Exercise | M | 0.00 | 1,278 | 0 | 0 | |
Feb 10 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Sell | S | 246.54 | 852 | 210,052 | 7,740 | 8.6 K to 7.7 K (-9.92 %) |
Feb 10 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 250.77 | 426 | 106,828 | 8,592 | 9 K to 8.6 K (-4.72 %) |
Feb 10 2016 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Buy | M | 0.00 | 1,278 | 0 | 9,018 | 7.7 K to 9 K (+16.51 %) |
Dec 07 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Sell | S | 277.00 | 441 | 122,157 | 7,740 | 8.2 K to 7.7 K (-5.39 %) |
Dec 07 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | EVP CMO Neuro & Neu ... | Payment of Exercise | F | 275.44 | 393 | 108,248 | 8,181 | 8.6 K to 8.2 K (-4.58 %) |
Sep 04 2015 | NBIX | NEUROCRINE BIOSCIE ... | Sandrock Alfred | Director | Option Exercise | A | 49.63 | 40,000 | 1,985,200 | 40,000 | |
Mar 30 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 430.12 | 430 | 184,952 | 8,574 | 9 K to 8.6 K (-4.78 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 411.39 | 1,000 | 411,390 | 9,004 | 10 K to 9 K (-10.00 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 410.57 | 374 | 153,554 | 10,004 | 10.4 K to 10 K (-3.60 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 408.98 | 600 | 245,388 | 10,378 | 11 K to 10.4 K (-5.47 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 407.95 | 1,100 | 448,743 | 10,978 | 12.1 K to 11 K (-9.11 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 406.40 | 100 | 40,640 | 12,078 | 12.2 K to 12.1 K (-0.82 %) |
Mar 03 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Payment of Exercise | F | 409.59 | 2,826 | 1,157,501 | 12,178 | 15 K to 12.2 K (-18.83 %) |
Feb 25 2015 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Option Exercise | A | 0.00 | 3,110 | 0 | 3,110 | |
Oct 23 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Option Exercise | M | 60.56 | 15,030 | 910,217 | 0 | |
Oct 23 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 250.11 | 15,030 | 3,759,123 | 14,500 | 29.5 K to 14.5 K (-50.90 %) |
Oct 23 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Buy | M | 60.56 | 15,030 | 910,217 | 29,530 | 14.5 K to 29.5 K (+103.66 %) |
Sep 18 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Option Exercise | M | 49.65 | 9,820 | 487,563 | 0 | |
Sep 18 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Sell | S | 240.10 | 9,820 | 2,357,821 | 14,500 | 24.3 K to 14.5 K (-40.38 %) |
Sep 18 2013 | IDPH | BIOGEN INC. | Sandrock Alfred | Grp SVP, Chief Medi ... | Buy | M | 49.65 | 9,820 | 487,563 | 24,320 | 14.5 K to 24.3 K (+67.72 %) |
Page: 1